Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus Docetaxel in Second-line Gastric Cancer
NCT03071042Phase 1Unknown
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Tolerance profile of participants with treatment-related adverse events at 4 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03071042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071042.